Checkpoint inhibitor resistance
Showing 1 - 25 of >10,000
Drug Resistance in Immune Checkpoint Inhibitors of Non-small
Recruiting
- Non-Small Cell Lung Cancer
- Anti-PD-1/PD-L1 monoclonal antibody
-
Shanghai, Shanghai, ChinaXiaomin Niu
Jul 24, 2021
Immune Checkpoint Inhibitor-related Cardiotoxicity
Not yet recruiting
- Immune Checkpoint Inhibitors, Cardiotoxicity
- Cardiac magnetic resonance
- (no location specified)
Nov 10, 2023
Severe Checkpoint Inhibitor Pneumonitis Trial in Beijing (Corticosteroids, Corticosteroids and Ruxolitinib)
Recruiting
- Severe Checkpoint Inhibitor Pneumonitis
- Corticosteroids
- Corticosteroids and Ruxolitinib
-
Beijing, Beijing, ChinaDepartment of Respiratory Medicine, Peking Union Medical College
Jun 12, 2023
Metastatic Pancreatic Cancer Trial in Rotterdam (Durvalumab, Rintatolimod)
Not yet recruiting
- Metastatic Pancreatic Cancer
- Durvalumab
- Rintatolimod
-
Rotterdam, Zuid-Holland, NetherlandsErasmus MC
Jun 23, 2023
Gastrointestinal Tumor Trial in Hangzhou (Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T,
Completed
- Gastrointestinal Tumor
- Water-filtered infrared A radiation whole-body hyperthermia (HECKEL 3000MT-4T, Germany)
- tislelizumab (BeiGene, China) combined with PD-1 inhibitor
-
Hangzhou, ChinaZhejiang Hospital
Sep 1, 2023
HCC Trial in Hong Kong (Zabadinostat (CXD101) and Geptanolimab, Lenvatinib and Sorafenib)
Not yet recruiting
- HCC
- Zabadinostat (CXD101) and Geptanolimab
- Lenvatinib and Sorafenib
-
Hong Kong, Hong KongDepartment of Clinical Oncology, Prince of Wales Hospital
May 15, 2023
Inflammatory Arthritis, Immune-related Adverse Event Trial (Adalimumab, Prednisone)
Not yet recruiting
- Inflammatory Arthritis
- Immune-related Adverse Event
- (no location specified)
Sep 13, 2023
Determine Pro-Inflammatory Cytokine Kinetics During Immune
Not yet recruiting
- Non Small Cell Lung Cancer
- Melanoma
-
Indianapolis, IndianaIndiana University Melvin and Bren Simon Comprehensive Cancer Ce
Jan 30, 2023
Malignant Ascites Trial in Taichung (Nivolumab, Pembrolizumab)
Enrolling by invitation
- Malignant Ascites
-
Taichung, Please Select, TaiwanChina Medical University Hospital
Feb 16, 2023
NSCLC Associated With Leptomeningeal Metastases Trial (Tislelizumab, pemetrexed)
Not yet recruiting
- NSCLC Associated With Leptomeningeal Metastases
- Tislelizumab, pemetrexed
- (no location specified)
Nov 21, 2023
Immune Checkpoint Inhibitor Monotherapy or Combined With
Not yet recruiting
- Immune Checkpoint Inhibitor Monotherapy or Combined With Molecular Targeting Drugs / Locoregional Therapy for Hepatocellular Carcinoma
- Immune checkpoint inhibitor
-
Guangzhou, Guangdong, ChinaDepartment of Minimally Invasive and Interventional Radiology, L
Jan 30, 2023
Lung Squamous Cell Carcinoma Trial in Yancheng (To explore the efficacy and safety of immune checkpoint inhibitor combined with
Recruiting
- Lung Squamous Cell Carcinoma
- To explore the efficacy and safety of immune checkpoint inhibitor combined with endostar and chemotherapy in the treatment of advanced lung squamous cell carcinoma (stage IIIB-IV).
-
Yancheng, Jiangsu, ChinaYancheng Clinical College of Xuzhou Medical University
Mar 21, 2023
Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitor, Radiotherapy Trial (radiation, drug, biological)
Not yet recruiting
- Nasopharyngeal Carcinoma
- +3 more
- Intensity Modulated Radiation Therapy
- +3 more
- (no location specified)
Jul 11, 2023
Advanced Biliary Tract Cancer Trial in Shanghai (Sintilimab, Lenvatinib, Cryoablation)
Recruiting
- Advanced Biliary Tract Cancer
- Sintilimab
- +2 more
-
Shanghai, Shanghai, ChinaFudan University Shanghai Cancer Center
Mar 22, 2023
Stage IV NSCLC Trial in Houston (Poly ICLC, IVIG)
Not yet recruiting
- Stage IV NSCLC
- Poly ICLC
- IVIG
-
Houston, TexasMichael E. DeBakey VA Medical Center, Houston, TX
Sep 28, 2023
Advanced Solid Tumor, Metastatic Solid Tumor Trial (PEP07)
Not yet recruiting
- Advanced Solid Tumor
- Metastatic Solid Tumor
- (no location specified)
Aug 1, 2023
EXploring Immune-related Adverse Events of Immune checkpoinT
Active, not recruiting
- Cancer
- +2 more
- Immune checkpoint inhibitor
-
Paris, France
- +1 more
Jul 5, 2023
Melanoma Trial in Toulouse (Nivolumab+Ipilimumab in combination with Anti TNF-a Certolizumab, Nivolumab+Ipilimumab in
Active, not recruiting
- Melanoma
- Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
- Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
-
Toulouse, FranceInstitut Claudius Regaud IUCT-ONCOPOLE
Nov 18, 2022
Development ofEORTC Immune Checkpoint Inhibitor-specific Quality
Recruiting
- Cancer
- +2 more
-
Paris, FranceInstitut Curie
Nov 2, 2022
Hepatocellular Carcinoma Trial in Shanghai (Anlotinib and TQB2450)
Not yet recruiting
- Hepatocellular Carcinoma
- Anlotinib and TQB2450
-
Shanghai, Shanghai, ChinaZhongshan hospital
Sep 4, 2023
Immune Checkpoint Inhibitors(ICPis)-Induced Endocrine
Completed
- Immune Checkpoint Inhibitor
- Endocrine Toxicity
-
Nanjing, Jiangsu, ChinaFirst Affiliated Hospital, Nanjing Medical University
Jan 6, 2023
Recurrent Nasopharyngeal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Chemo Effect Trial in Guangzhou (PD-1 Immune Checkpoint
Active, not recruiting
- Recurrent Nasopharyngeal Carcinoma
- +2 more
- PD-1 Immune Checkpoint Inhibitor Combined With Bevacizumab
-
Guangzhou, Guangdong, ChinaYanqun Xiang
Sep 5, 2022
